Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Rossignol

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2003
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonistMaureen Mullarkey, Jeffrey R Rose, John Bristol, et al.
The Journal of Infectious Diseases|February 25, 2003
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemiaMelvyn Lynn, Daniel P Rossignol, Janice L Wheeler, et al.
Antimicrobial Agents and Chemotherapy|August 26, 2003
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrationsKishor M Wasan, Olena Sivak, Richard A Cote, et al.
Pharmaceutical Research|September 13, 2007
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbitsKishor M Wasan, Verica Risovic, Olena Sivak, et al.
British Journal of Pharmacology|August 5, 1999
E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharideT Kawata, J R Bristol, D P Rossignol, et al.
Biochemical Pharmacology|July 15, 1990
Pumiliotoxin alkaloids: a new class of sodium channel agentsJ W Daly, F Gusovsky, E T McNeal, et al.
Innate Immunity|March 31, 2012
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian menNaoki Aikawa, Yoshio Okubo, Melvyn Lynn, et al.
Progress in Clinical and Biological Research|January 1, 1995
Anti-endotoxin activity of a novel synthetic lipid A analogT Kawata, J R Bristol, J R Rose, et al.
Anesthesia and Analgesia|January 24, 2007
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypassElliott Bennett-Guerrero, Hilary P Grocott, Jerrold H Levy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
The Journal of Pharmacology and Experimental Therapeutics|February 27, 2003
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonistMaureen Mullarkey, Jeffrey R Rose, John Bristol, et al.
The Journal of Infectious Diseases|February 25, 2003
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemiaMelvyn Lynn, Daniel P Rossignol, Janice L Wheeler, et al.
Antimicrobial Agents and Chemotherapy|August 26, 2003
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrationsKishor M Wasan, Olena Sivak, Richard A Cote, et al.
Pharmaceutical Research|September 13, 2007
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbitsKishor M Wasan, Verica Risovic, Olena Sivak, et al.
British Journal of Pharmacology|August 5, 1999
E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharideT Kawata, J R Bristol, D P Rossignol, et al.
Biochemical Pharmacology|July 15, 1990
Pumiliotoxin alkaloids: a new class of sodium channel agentsJ W Daly, F Gusovsky, E T McNeal, et al.
Innate Immunity|March 31, 2012
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian menNaoki Aikawa, Yoshio Okubo, Melvyn Lynn, et al.
Progress in Clinical and Biological Research|January 1, 1995
Anti-endotoxin activity of a novel synthetic lipid A analogT Kawata, J R Bristol, J R Rose, et al.
Anesthesia and Analgesia|January 24, 2007
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypassElliott Bennett-Guerrero, Hilary P Grocott, Jerrold H Levy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2011
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignanciesMonica Mita, Kevin R Kelly, Alain Mita, et al.
Pageof 8